Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
View/ Open
Author
Tang, Tracy
Tang, Jean Y.
Li, Dongwei
Reich, Mike
Callahan, Christopher A.
Fu, Ling
Yauch, Robert L.
Wang, Frank
Kotkow, Karen
Chang, Kris S.
Shpall, Elana
Wu, Angela
Marsters, James C., Jr.
Epstein, Ervin H., Jr.
Caro, Ivor
de Sauvage, Frederic J.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1158/1078-0432.CCR-10-3370Metadata
Show full item recordCitation
Tang, Tracy, Jean Y. Tang, Dongwei Li, Mike Reich, Christopher A. Callahan, Ling Fu, Robert L. Yauch, et al. 2011. Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened. Clinical Cancer Research 17, no. 10: 3378–3387.Abstract
Purpose: Inappropriate activation of the Hedgehog (Hh) signaling pathway in skin is critical for the development of basal cell carcinomas (BCC). We have investigated the anti-BCC efficacy of topically-applied CUR61414, an inhibitor of the Hh signal transduction molecule Smoothened.Experimental Design: In preclinical studies, we used a depilatory model to evaluate the ability of topical formulations of CUR61414 to repress Hh responsive cells found at the base of hair follicles in normal skin. We also tested the in vivo effects of topical CUR61414 on murine BCCs developed in \(Ptch1^{ +/−}\) K14-CreER2 p53 fl/fl mice. In a phase I clinical study, we evaluated the safety, tolerability, and efficacy of a multidose regimen of CUR61414 (0.09%, 0.35%, 1.1%, and 3.1%) applied topically to human superficial or nodular BCCs for up to 28 days.
Results: In mice, topical CUR61414 significantly inhibited skin Hh signaling, blocked the induction of hair follicle anagen, and shrank existing BCCs. However, we observed no clinical activity of this formulation in human superficial or nodular BCCs in a phase I clinical study.
Conclusions: Our data highlight some of the challenges of translating preclinical experience into successful human results for a topical anticancer agent.
Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113453/Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAPCitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12992309
Collections
- FAS Scholarly Articles [18256]
Contact administrator regarding this item (to report mistakes or request changes)